Why the study?
Hospitalizations for decompensated HF and associated costs are steadily increasing, marking disease progression and high risk of adverse events during the post-discharge vulnerable period.
Highlights the critical importance of optimizing disease-modifying therapy and care organization during the high-risk vulnerable period following hospitalization for decompensated HFrEF.
HF hospitalization signals high risk in HFrEF; leaves open strategies to overcome management barriers.
Frequency of hospitalizations for decompensated heart failure (HF) and associated costs are steadily increasing worldwide. An episode of HF is a risk marker, reflects a change in the course of disease, a high probability of adverse events, and requirement for using all options to improve the prognosis. This article discusses barriers and ways to overcome them in managing HF patients with low ejection fraction. An evidence-based, disease-modifying therapy exists for this HF phenotype. Administration of the therapy along with additional, novel drugs that improve outcomes, and organization of medical care are essential during the "vulnerable period" after discharge from the hospital.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: